Point72 Asset Management L.P. Reduces Stock Position in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Point72 Asset Management L.P. lessened its stake in GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 76.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 381,903 shares of the company's stock after selling 1,245,687 shares during the period. Point72 Asset Management L.P. owned about 0.10% of GoodRx worth $1,776,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. National Bank of Canada FI lifted its stake in shares of GoodRx by 34.9% in the 4th quarter. National Bank of Canada FI now owns 8,308 shares of the company's stock valued at $39,000 after purchasing an additional 2,151 shares during the period. RPO LLC purchased a new stake in GoodRx during the fourth quarter worth $52,000. Versor Investments LP purchased a new stake in GoodRx during the fourth quarter worth $54,000. Verus Capital Partners LLC purchased a new stake in GoodRx during the fourth quarter worth $55,000. Finally, Steward Partners Investment Advisory LLC purchased a new stake in GoodRx during the fourth quarter worth $56,000. Hedge funds and other institutional investors own 63.77% of the company's stock.

Wall Street Analyst Weigh In

GDRX has been the topic of a number of recent analyst reports. Truist Financial lowered their price target on shares of GoodRx from $6.50 to $5.50 and set a "hold" rating on the stock in a report on Thursday, April 10th. UBS Group lowered their price target on GoodRx from $6.00 to $5.25 and set a "neutral" rating on the stock in a research report on Tuesday, May 13th. The Goldman Sachs Group lowered their price target on GoodRx from $6.00 to $5.00 and set a "neutral" rating on the stock in a research report on Friday, May 9th. Finally, Wells Fargo & Company lowered their price target on GoodRx from $8.00 to $7.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 29th. Five research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, GoodRx has an average rating of "Moderate Buy" and an average price target of $6.55.

GoodRx Price Performance

Shares of GDRX traded down $0.08 during trading hours on Friday, hitting $3.74. 1,188,481 shares of the stock were exchanged, compared to its average volume of 1,386,733. The stock's 50-day moving average price is $4.38 and its two-hundred day moving average price is $4.59. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48. The company has a market cap of $1.34 billion, a price-to-earnings ratio of -124.67, a price-to-earnings-growth ratio of 2.46 and a beta of 1.24. GoodRx Holdings, Inc. has a 12-month low of $3.68 and a 12-month high of $9.26.

GoodRx (NASDAQ:GDRX - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.09 EPS for the quarter, beating analysts' consensus estimates of $0.04 by $0.05. The business had revenue of $202.97 million during the quarter, compared to analysts' expectations of $202.25 million. GoodRx had a negative net margin of 2.05% and a positive return on equity of 5.35%. The company's quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.08 earnings per share. Research analysts expect that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current year.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.